William R Proctor
Overview
Explore the profile of William R Proctor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
758
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loberg L, Proctor W, Burdick A, Cauvin A, DeLise A, Hemkens M, et al.
Regul Toxicol Pharmacol
. 2025 Feb;
158:105793.
PMID: 40015443
Targeted protein degraders (or degraders) are an emerging small molecule drug modality with transformative therapeutic potential. Currently, most degraders are developed for severe life-threatening disorders and engage the E3 ligase...
2.
Chutake Y, Mayo M, Dumont N, Filiatrault J, Breitkopf S, Cho P, et al.
Mol Cancer Ther
. 2024 Dec;
PMID: 39648478
Murine double minute 2 (MDM2) is an E3 ligase that inhibits the tumor suppressor protein p53. Clinical trials employing small-molecule MDM2/p53 interaction inhibitors (SMIs) have demonstrated limited activity, underscoring an...
3.
Baran S, Brown P, Baudy A, Fitzpatrick S, Frantz C, Fullerton A, et al.
ALTEX
. 2022 Jan;
39(2):297–314.
PMID: 35064273
Complex in vitro models (CIVM) offer the potential to improve pharmaceutical clinical drug attrition due to safety and/ or efficacy concerns. For this technology to have an impact, the establishment...
4.
Wang H, Brown P, Chow E, Ewart L, Ferguson S, Fitzpatrick S, et al.
Clin Transl Sci
. 2021 May;
14(5):1659-1680.
PMID: 33982436
Nonclinical testing has served as a foundation for evaluating potential risks and effectiveness of investigational new drugs in humans. However, the current two-dimensional (2D) in vitro cell culture systems cannot...
5.
Norona L, Fullerton A, Lawson C, Leung L, Brumm J, Kiyota T, et al.
Arch Toxicol
. 2020 Jun;
94(9):3185-3200.
PMID: 32583097
Drug-induced liver injury (DILI) continues to be a major cause of drug attrition and restrictive labeling. Given the importance of farnesoid X receptor (FXR) in bile acid homeostasis, drug-related FXR...
6.
Fabre K, Berridge B, Proctor W, Ralston S, Will Y, Baran S, et al.
Lab Chip
. 2020 Feb;
20(6):1049-1057.
PMID: 32073020
Safety related drug failures continue to be a challenge for pharmaceutical companies despite the numerous complex and lengthy in vitro assays and in vivo studies that make up the typical...
7.
Baudy A, Otieno M, Hewitt P, Gan J, Roth A, Keller D, et al.
Lab Chip
. 2019 Dec;
20(2):215-225.
PMID: 31799979
The liver is critical to consider during drug development because of its central role in the handling of xenobiotics, a process which often leads to localized and/or downstream tissue injury....
8.
Vogt J, Sheinson D, Katavolos P, Irimagawa H, Tseng M, Alatsis K, et al.
PLoS One
. 2019 Jul;
14(7):e0220406.
PMID: 31348817
Micro-RNA (miR)-122 is a promising exploratory biomarker for detecting liver injury in preclinical and clinical studies. Elevations in serum or plasma have been associated with viral and autoimmune hepatitis, non-alcoholic...
9.
McKerrall S, Nguyen T, Lai K, Bergeron P, Deng L, DiPasquale A, et al.
J Med Chem
. 2019 Apr;
62(8):4091-4109.
PMID: 30943032
Using structure- and ligand-based design principles, a novel series of piperidyl chromane arylsulfonamide Na1.7 inhibitors was discovered. Early optimization focused on improvement of potency through refinement of the low energy...
10.
Jarzabek M, Proctor W, Vogt J, Desai R, Dicker P, Cain G, et al.
PLoS One
. 2018 Jun;
13(6):e0198099.
PMID: 29879147
Drug-related sinusoidal dilatation (SD) is a common form of hepatotoxicity associated with oxaliplatin-based chemotherapy used prior to resection of colorectal liver metastases (CRLM). Recently, hepatic SD has also been associated...